Advertisement

AIDS and Behavior

, Volume 23, Issue 1, pp 190–200 | Cite as

Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings

  • Onyema OgbuaguEmail author
  • Brandon D. L. Marshall
  • Perry Tiberio
  • Adedotun Ogunbajo
  • Lydia Barakat
  • Madeline Montgomery
  • Alexi Almonte
  • Tyler Wray
  • Emily C. Williams
  • E. Jennifer Edelman
  • Philip A. Chan
Original Paper

Abstract

Pre-exposure prophylaxis (PrEP) is effective in preventing HIV acquisition among men who have sex with men (MSM). However, little is known about unhealthy substance use among MSM initiating PrEP in real-world settings. Unhealthy substance use is a risk factor for HIV acquisition and non-adherence to treatment, and may also impact PrEP use. MSM who were prescribed PrEP from 2015 to 2017 at clinics in Providence, Rhode Island and New Haven, Connecticut were recruited to participate in a prospective observational study. Structured clinical assessments were used to assess demographics, HIV risk behaviors, and unhealthy alcohol (alcohol use disorders identification test [AUDIT]-C scores ≥ 4) and drug use (use of any drugs in the past 3 months). Bivariate and multivariate analyses were performed to determine demographics and behaviors associated with unhealthy alcohol and drug use. Among 172 MSM initiating PrEP, 64% were white and 40% were 25–34 years old. Participants reported a median of 3 (IQR 2–7) sexual partners in the last 3 months; 20% reported an HIV positive partner. Unhealthy alcohol and any drug use were reported by 54 and 57%, respectively, and 76% reported at least one of the two. The majority of drug use reported was marijuana and poppers (41 and 26% of participants, respectively). Relative to those without unhealthy alcohol use, unhealthy alcohol use was independently associated with any drug use (adjusted odds ratio [AOR] = 2.57, 95% CI 1.32–5.01). Frequent drug use was associated with younger age (< 25 years, AOR 4.27, 95% CI 1.51–12.09). Unhealthy alcohol use is common among MSM taking PrEP. Drug use other than marijuana and poppers was uncommon among our cohort. Further efforts may be needed to understand the influence of unhealthy alcohol and other substance use on PrEP outcomes and to engage MSM who use drugs for PrEP.

Keywords

Pre-exposure prophylaxis Alcohol Implementation Men who have sex with men HIV 

Notes

Acknowledgements

Support for study authors: PAC is supported by the National Institute Health (R01MH114657). EJE was supported as a Yale Drug Abuse, Addiction and HIV Research Scholars (DAHRS) Program during the conduct of this work (K12DA033312).

Funding

This study was funded by Lifespan/Tufts/Brown Center for AIDS Research (Grant No. P30AI042853) and the Yale Center for Interdisciplinary Research on AIDS (Grant No. 5P30MH62294) and also National Institutes of Health (Grant Nos. R34DA042648, R34MH110369, R34MH109371, R21MH113431, R21MH109360) and National Institutes of Health (US) (Grant No. K12DA033312).

Compliance with Ethical Standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Centers for Disease Control and Prevention. HIV surveillance report: diagnoses of HIV Infection in the United States and Dependent Areas (2016). https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-vol-28.pdf. Accessed 27 May 2018.
  2. 2.
    Centers for Disease Control and Prevention. Lifetime risk of HIV diagnosis (2017). https://www.cdc.gov/nchhstp/newsroom/2016/croi-press-release-risk.html. Accessed 24 Feb 2017.
  3. 3.
    Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2(5):e27.CrossRefGoogle Scholar
  4. 4.
    Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefGoogle Scholar
  5. 5.
    McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60.CrossRefGoogle Scholar
  6. 6.
    Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.CrossRefGoogle Scholar
  7. 7.
    Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefGoogle Scholar
  8. 8.
    CDC. Vital signs: estimated percentages and numbers of adults with indications for preexposure prophylaxis to prevent HIV acquisition—United States. Morb Mortal Wkly Rep. 2015;64(46):1291–5.CrossRefGoogle Scholar
  9. 9.
    Sewell J, Miltz A, Lampe FC, et al. Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics. Int J Drug Policy. 2017;43:33–43.CrossRefGoogle Scholar
  10. 10.
    Wang HY, Xu JJ, Zou HC, et al. Sexual risk behaviors and HIV infection among men who have sex with men and women in China: evidence from a systematic review and meta-analysis. Biomed Res Int. 2015;2015:850132.Google Scholar
  11. 11.
    Baliunas D, Rehm J, Irving H, Shuper P. Alcohol consumption and risk of incident human immunodeficiency virus infection: a meta-analysis. Int J Public Health. 2010;55(3):159–66.CrossRefGoogle Scholar
  12. 12.
    Yadav D, Chakrapani V, Goswami P, et al. Association between alcohol use and HIV-related sexual risk behaviors among men who have sex with men (MSM): findings from a multi-site bio-behavioral survey in India. AIDS Behav. 2014;18(7):1330–8.CrossRefGoogle Scholar
  13. 13.
    Goedel WC, Duncan DT. Correlates of engagement in group sex events among men who have sex with men in London who use geosocial-networking smartphone applications. Int J STD AIDS. 2017;29:244–50.CrossRefGoogle Scholar
  14. 14.
    Saitz R. Clinical practice. Unhealthy alcohol use. N Engl J Med. 2005;352(6):596–607.CrossRefGoogle Scholar
  15. 15.
    Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170(13):1155–60.CrossRefGoogle Scholar
  16. 16.
    Stall R, Paul JP, Greenwood G, et al. Alcohol use, drug use and alcohol-related problems among men who have sex with men: the Urban Men’s Health Study. Addiction. 2001;96(11):1589–601.CrossRefGoogle Scholar
  17. 17.
    Ryan CM, Huggins J, Beatty R. Substance use disorders and the risk of HIV infection in gay men. J Stud Alcohol. 1999;60(1):70–7.CrossRefGoogle Scholar
  18. 18.
    Hess KL, Chavez PR, Kanny D, DiNenno E, Lansky A, Paz-Bailey G. Binge drinking and risky sexual behavior among HIV-negative and unknown HIV status men who have sex with men, 20 US cities. Drug Alcohol Depend. 2015;147:46–52.CrossRefGoogle Scholar
  19. 19.
    Williams EC, Hahn JA, Saitz R, Bryant K, Lira MC, Samet JH. Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions. Alcohol Clin Exp Res. 2016;40(10):2056–72.CrossRefGoogle Scholar
  20. 20.
    Chan PA, Glynn TR, Oldenburg CE, et al. Implementation of preexposure prophylaxis for human immunodeficiency virus prevention among men who have sex with men at a New England sexually transmitted diseases clinic. Sex Transm Dis. 2016;43(11):717–23.CrossRefGoogle Scholar
  21. 21.
    Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefGoogle Scholar
  22. 22.
    Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRefGoogle Scholar
  23. 23.
    Hojilla JC, Vlahov D, Glidden DV, et al. Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis. J Int AIDS Soc. 2018;21(3):e25103.CrossRefGoogle Scholar
  24. 24.
    White JM, Gordon JR, Mimiaga MJ. The role of substance use and mental health problems in medication adherence among HIV-infected MSM. LGBT Health. 2014;1(4):319–22.CrossRefGoogle Scholar
  25. 25.
    Okafor CN, Gorbach PM, Ragsdale A, Quinn B, Shoptaw S. Correlates of preexposure prophylaxis (PrEP) use among men who have sex with men (MSM) in Los Angeles, California. J Urban Health. 2017;94(5):710–5.CrossRefGoogle Scholar
  26. 26.
    Grodensky CA, Golin CE, Ochtera RD, Turner BJ. Systematic review: effect of alcohol intake on adherence to outpatient medication regimens for chronic diseases. J Stud Alcohol Drugs. 2012;73(6):899–910.CrossRefGoogle Scholar
  27. 27.
    Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14(4):731–47.CrossRefGoogle Scholar
  28. 28.
    Korthuis PT, Fiellin DA, McGinnis KA, et al. Unhealthy alcohol and illicit drug use are associated with decreased quality of HIV care. J Acquir Immune Defic Syndr. 2012;61(2):171–8.CrossRefGoogle Scholar
  29. 29.
    Monroe AK, Lau B, Mugavero MJ, et al. Heavy alcohol use is associated with worse retention in HIV care. J Acquir Immune Defic Syndr. 2016;73(4):419–25.CrossRefGoogle Scholar
  30. 30.
    Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA. 1999;282(18):1737–44.CrossRefGoogle Scholar
  31. 31.
    Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. ambulatory care quality improvement project (ACQUIP). alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.CrossRefGoogle Scholar
  32. 32.
    Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31(7):1208–17.CrossRefGoogle Scholar
  33. 33.
    Kahler CW, Wray TB, Pantalone DW, et al. Daily associations between alcohol use and unprotected anal sex among heavy drinking HIV-positive men who have sex with men. AIDS Behav. 2015;19(3):422–30.CrossRefGoogle Scholar
  34. 34.
    Kalichman SC, Kalichman MO, Cherry C, Grebler T. HIV disclosure and transmission risks to sex partners among HIV-positive men. AIDS Patient Care STDS. 2016;30(5):221–8.CrossRefGoogle Scholar
  35. 35.
    Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014;18(9):1694–700.CrossRefGoogle Scholar
  36. 36.
    Edelman EJ, Moore BA, Calabrese SK, et al. Primary care physicians’ willingness to prescribe HIV pre-exposure prophylaxis for people who inject drugs. AIDS Behav. 2017;21(4):1025–33.CrossRefGoogle Scholar
  37. 37.
    Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefGoogle Scholar
  38. 38.
    Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives. Subst Abuse Treat Prev Policy. 2015;10:1.CrossRefGoogle Scholar
  39. 39.
    Smith-Rohrberg D, Mezger J, Walton M, Bruce RD, Altice FL. Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S48–53.CrossRefGoogle Scholar
  40. 40.
    Wolfe H, Haller DL, Benoit E, et al. Developing PeerLink to engage out-of-care HIV+ substance users: training peers to deliver a peer-led motivational intervention with fidelity. AIDS Care. 2013;25(7):888–94.CrossRefGoogle Scholar
  41. 41.
    Morgan E, Skaathun B, Michaels S, et al. Marijuana use as a sex-drug is associated with HIV risk among black MSM and their network. AIDS Behav. 2016;20(3):600–7.CrossRefGoogle Scholar
  42. 42.
    Brown RE, Turner C, Hern J, Santos GM. Partner-level substance use associated with increased sexual risk behaviors among men who have sex with men in San Francisco, CA. Drug Alcohol Depend. 2017;176:176–80.CrossRefGoogle Scholar
  43. 43.
    Marcus JL, Hurley LB, Hare CB, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr. 2016;73(5):540–6.CrossRefGoogle Scholar
  44. 44.
    Latkin CA, Mai NV, Ha TV, et al. Social desirability response bias and other factors that may influence self-reports of substance use and HIV risk behaviors: a qualitative study of drug users in Vietnam. AIDS Educ Prev. 2016;28(5):417–25.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Onyema Ogbuagu
    • 1
    Email author
  • Brandon D. L. Marshall
    • 2
  • Perry Tiberio
    • 3
  • Adedotun Ogunbajo
    • 2
  • Lydia Barakat
    • 1
  • Madeline Montgomery
    • 4
  • Alexi Almonte
    • 4
  • Tyler Wray
    • 5
  • Emily C. Williams
    • 6
    • 7
  • E. Jennifer Edelman
    • 8
    • 9
  • Philip A. Chan
    • 4
    • 5
  1. 1.Yale AIDS Program, Section of Infectious DiseasesYale University School of MedicineNew HavenUSA
  2. 2.Department of EpidemiologyBrown University School of Public HealthProvidenceUSA
  3. 3.Department of MedicineYale-New Haven HospitalNew HavenUSA
  4. 4.Department of MedicineBrown UniversityProvidenceUSA
  5. 5.Department of Behavioral and Social SciencesBrown University School of Public HealthProvidenceUSA
  6. 6.Department of Health ServicesUniversity of Washington School of Public HealthSeattleUSA
  7. 7.Health Services Research & Development Center of Innovation for Veteran Centered and Value-Driven CareVA Puget SoundSeattleUSA
  8. 8.Section of General Internal Medicine, Department of MedicineYale School of MedicineNew HavenUSA
  9. 9.Center for Interdisciplinary Research on AIDSYale School of Public HealthNew HavenUSA

Personalised recommendations